Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial
Cemiplimab+peltopepimut-S vaccine provides similar benefits to cemiplimab monotherapy; patients with higher PD-L1 expression in tumor cells may be more likely to benefit from treatment.
Authors
- Hannelore Denys (ORCID: https://orcid.org/0000-0002-8897-9430)
- Anna K.L. Reyners (ORCID: https://orcid.org/0000-0003-1678-7816)
- Frank Seebach
- Judith R. Kroep (ORCID: https://orcid.org/0000-0003-2671-1903)
- Suk‐Young Yoo
- Leon Hooftman
- Nicoletta Colombo (ORCID: https://orcid.org/0000-0002-4197-2506)
- Melissa Mathias (ORCID: https://orcid.org/0000-0001-6026-601X)
- Lisa Boersma
- Andréia Cristina de Melo (ORCID: https://orcid.org/0000-0002-1201-4333)
- Israel Lowy (ORCID: https://orcid.org/0000-0002-5421-2485)
- Cornelis J.M. Melief (ORCID: https://orcid.org/0000-0001-5709-3584)
- Yong‐Man Kim
- Roy Lalisang (ORCID: https://orcid.org/0000-0002-9752-0947)
- Carlos Eduardo Paiva (ORCID: https://orcid.org/0000-0002-7934-1451)
- Nelleke Ottevanger
- Domenica Lorusso (ORCID: https://orcid.org/0000-0003-0981-0598)
- Matthew G. Fury
- Toon Van Gorp (ORCID: https://orcid.org/0000-0002-2564-721X)
- Andrés Redondo (ORCID: https://orcid.org/0000-0002-7257-5642)
- Celine Closset
- Fernanda Damian (ORCID: https://orcid.org/0000-0003-4651-3357)
- Jae Kwan Lee (ORCID: https://orcid.org/0000-0003-3101-6403)
- Hee‐Seung Kim (ORCID: https://orcid.org/0000-0002-5421-1108)
- Paulo Mora (ORCID: https://orcid.org/0000-0003-1756-3320)
- Giuliano Santos Borges
- Shaheda Jamil
- Ana Oaknin
Institutions
- University Medical Center Groningen (NL)
- Seoul National University (KR)
- Radboud University Nijmegen (NL)
- University of Groningen (NL)
- Regeneron (United States) (US)
- Korea University Medical Center (KR)
- Leiden University Medical Center (NL)
- Maastricht University Medical Centre (NL)
- Hospital Universitario La Paz (ES)
- Ghent University Hospital (BE)
- Asan Medical Center (KR)
- Agostino Gemelli University Polyclinic (IT)
- Radboud University Medical Center (NL)
- Maastricht University (NL)
- University of Ulsan (KR)
- ISA Pharmaceuticals (Netherlands) (NL)
- The European Academy of Gynaecological Surgery (BE)
- Hospital de Câncer de Barretos (BR)
- Hospital do Câncer III (BR)
- Vall d'Hebron Hospital Universitari (ES)
- Centre Hospitalier Interrégional Edith Cavell (BE)
- Instituto Nacional de Câncer - INCA (BR)
- Centro de Pesquisas Oncológicas (BR)
- Vall d'Hebron Institute of Oncology (ES)
- European Institute of Oncology (IT)
- KU Leuven (BE)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1016/j.ygyno.2025.03.019
- Citations
- 3
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Teva Pharmaceutical Industries
- American Society of Clinical Oncology
- F. Hoffmann-La Roche
- Karyopharm Therapeutics
- Regeneron Pharmaceuticals
- Iowa Soybean Association
- Novocure
- Les Laboratories Pierre Fabre
- Clovis Oncology
- Sarepta Therapeutics
- Deciphera Pharmaceuticals
- Mersana Therapeutics
- Myriad Genetics
- BeiGene
- Incyte
- Seagen
- Eisai
- European Society for Medical Oncology
- Sociedad Española de Oncología Médica
- PharmaMar
- Genentech
- EMD Serono
- Chugai Pharmaceutical
- Daiichi Sankyo Europe